Crescita Therpeutc (TSE:CTX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Crescita Therapeutics has announced an exclusive agreement to distribute the MicronJet 600, the world’s smallest intradermal delivery device, in Canada’s medical aesthetics market. The device promises precise, minimally invasive, and comfortable injections, an innovation welcomed by practitioners and patients. It is already CE marked and FDA cleared, with Crescita planning a Canadian launch in the first half of 2025, post Health Canada approval.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.